Neoantigen peptide vaccine

drug_type

RELEVANT_DRUG

intervention_type

Vaccine (synthetic peptide)

drug_description

Patient-specific synthetic peptide mixture of tumor neoantigens administered as a vaccine to elicit CD8+ and CD4+ T-cell responses via HLA class I/II presentation.

nci_thesaurus_concept_id

C165508

nci_thesaurus_preferred_term

Neoantigen Peptide Vaccine

nci_thesaurus_definition

A peptide-based cancer vaccine consisting of patient-specific antigens, which are immunogenic and unique to the patients tumor, with potential immunomodulating and antineoplastic activities. Upon vaccination with the neoantigen peptide vaccine, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.

drug_mesh_term

Peptide Vaccines

drug_category

PEPTIDE VACCINE

drug_class

Vaccine

drug_delivery_route

Subcutaneous

drug_mechanism_of_action

Patient-specific synthetic neoantigen peptides are taken up by antigen-presenting cells and presented on HLA class I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells that recognize and lyse tumor cells expressing those neoantigens and can generate antitumor immune memory.

drug_name

Neoantigen peptide vaccine

nct_id_drug_ref

NCT05749627